2023–2024 Article Series of the Canadian Association of General Practitioners in Oncology

A special issue of Current Oncology (ISSN 1718-7729).

Deadline for manuscript submissions: 31 December 2024 | Viewed by 2890

Special Issue Editor


E-Mail Website
Guest Editor
McGill University Health Centre, Division of Oncology and Family Medicine, McGill University, Montreal, QC H8S 3N5, Canada
Interests: cancer survivorship; communication in healthcare; palliative medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The Canadian Association of General Practitioners in Oncology (CAGPO) is pleased to continue its partnership with Current Oncology for their fourth 2023–2024 article series targeting health professionals involved in oncology and palliative care. Stay tuned for what will surely be another excellent six-article educational series with the contributions of recognized experts on the latest cancer and supportive care topics.

Dr. Genevieve Chaput
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

Jump to: Review, Other

2 pages, 178 KiB  
Editorial
Oncology Workforce Crisis: Let’s Work Smarter, Not Harder
by Genevieve Chaput
Curr. Oncol. 2023, 30(12), 10408-10409; https://doi.org/10.3390/curroncol30120758 - 11 Dec 2023
Cited by 1 | Viewed by 859
Abstract
Editorial: Cancer projections in Canada are bleak, with the average annual number of new cancer diagnoses expected to be 79% higher in 2028–2032 compared to 2003–2007 [...] Full article

Review

Jump to: Editorial, Other

16 pages, 1516 KiB  
Review
Contemporary Systemic Therapy Intensification for Prostate Cancer: A Review for General Practitioners in Oncology
by Anupam Batra, Daniel Glick and Mario Valdes
Curr. Oncol. 2024, 31(2), 1047-1062; https://doi.org/10.3390/curroncol31020078 - 15 Feb 2024
Viewed by 1217
Abstract
Prostate cancer accounts for a significant proportion of cancer diagnoses in Canadian men. Over the past decade, the therapeutic landscape for the management of metastatic prostate cancer has undergone rapid changes. Novel strategies use hormonal agents, chemotherapy, homologous recombination repair inhibitors, and radioligand [...] Read more.
Prostate cancer accounts for a significant proportion of cancer diagnoses in Canadian men. Over the past decade, the therapeutic landscape for the management of metastatic prostate cancer has undergone rapid changes. Novel strategies use hormonal agents, chemotherapy, homologous recombination repair inhibitors, and radioligand therapy or combination strategies in addition to androgen deprivation therapy. In this review, we summarize the available data addressing key therapeutic areas along the disease continuum and focus on practical aspects for general practitioners in oncology managing patients with metastatic prostate cancer. Full article
Show Figures

Figure 1

Other

Jump to: Editorial, Review

7 pages, 203 KiB  
Commentary
A Review of Practice-Changing Therapies in Oncology in the Era of Personalized Medicine
by Mariana Pilon Capella and Khashayar Esfahani
Curr. Oncol. 2024, 31(4), 1913-1919; https://doi.org/10.3390/curroncol31040143 - 02 Apr 2024
Viewed by 500
Abstract
In the past decade, a lot of insight was gathered into the composition of the host and tumor factors that promote oncogenesis and treatment resistance. This in turn has led to the ingenious design of multiple new classes of drugs, which have now [...] Read more.
In the past decade, a lot of insight was gathered into the composition of the host and tumor factors that promote oncogenesis and treatment resistance. This in turn has led to the ingenious design of multiple new classes of drugs, which have now become the new standards of care in cancer therapy. These include novel antibody-drug conjugates, chimeric antigen receptor T cell therapies (CAR-T), and bispecific T cell engagers (BitTE). Certain host factors, such as the microbiome composition, are also emerging not only as biomarkers for the response and toxicity to anti-cancer therapies but also as potentially useful tools to modulate anti-tumor responses. The field is slowly moving away from one-size-fits-all treatment options to personalized treatments tailored to the host and tumor. This commentary aims to cover the basic concepts associated with these emerging therapies and the promises and challenges to fight cancer. Full article
Back to TopTop